For Immediate Release

April 19, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, today announced that it will participate in this year’s Bloom Burton & Co. Healthcare Investor Conference in Toronto, Canada. The event takes place May 1-2, 2017 at the Sheraton Centre Toronto Hotel.

Appili’s Chief Financial Officer, Kimberly Stephens, will present a corporate overview and update on Monday, May 1, 2017 at 1:30 p.m. ET in Hall B, Lower Concourse Level of the Sheraton Centre Toronto Hotel.

Ms. Stephens’ presentation will focus on market potential of Appili’s anti-infective pipeline as the company advances its late-stage and early-stage antibiotic candidates. She will discuss the future clinical path for its lead product, ATI-1501, a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile, as well as the Company’s earlier-stage product, ATI-1503, a novel antibiotic that targets Gram-negative bacteria.

Investors interested in arranging a meeting with Ms. Stephens during this conference should contact Bloom Burton & Co.’s conference coordinator.

 

About the Conference

Bloom Burton & Co. is hosting its sixth annual Healthcare Investor Conference on May 1 and 2, 2017 at the Sheraton Centre Toronto Hotel, Toronto, Canada. The Company aims to showcase approximately 60 of Canada’s premier healthcare companies to its network of international investors. The conference includes networking sessions, keynote speeches and panel discussions with venture capital, public equity and strategic investors. The event attracts investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies and participate in 1-on-1 meetings with company management.

 

About Appili Therapeutics

Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections, including C. difficile. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat drug-resistant Gram-negative infections, including Klebsiella pneumoniae, Acinetobactor baumannii, and Pseudomonas aeruginosa. These drug-resistant infections have been identified by the Centers for Disease Control and Prevention as posing the highest threat to human health. For more information visit www.AppiliTherapeutics.com.

Media Relations Contact:

Jennifer Cameron

T: 902-209-4704

E: Media@AppiliTherapeutics.com

 

Investor Relations Contact:

Kimberly Stephens, CFO

Appili Therapeutics

E: Info@AppiliTherapeutics.com